EATG » Immune response

Immune response

Effects of the anti-inflammatory antibody canakinumab on heart disease and cancer: implications for HIV?

Inflammation is increasingly recognized as an immunological double-edged sword: it contributes importantly to the response to infection, but can also cause serious collateral damage to the body—particularly when persistent—and has…

Immune response to HIV linked to cancer mutations

University of Saskatchewan researchers have found the onset of breast, lung and other cancers may be connected to malfunctions of the immune system as it combats specific viruses such as…

World first: scientists find where HIV ‘hides’ to evade detection by the immune system

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious…

Long-acting monoclonal antibody effective against multidrug-resistant HIV

Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited treatment options, according to a…

Three-in-one antibody protects monkeys from HIV-like virus

NIH and Sanofi scientists prepare to test antibody in people. A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of…

Five-drug early HIV treatment does not correct inflammation or immune deficits

Starting five-drug antiretroviral therapy (ART) in the first months of infection did not quell HIV-associated inflammation in a 22-man randomized comparison with standard ART. Intensified ART had little impact on…

STEPS IV Cure Workshop in Milan on 24/10/2017

If you are planning to attend the EACS meeting in Milan, Italy (October 25-27), you are invited to apply to the fourth community meeting focused on HIV cure, therapeutic vaccines…

VRC01 antibody prolonged time to HIV viral rebound after treatment interruption

Study administered broadly neutralizing antibody infusions to virally suppressed volunteers who initiated ART during acute HIV infection July 25, 2017 (PARIS) -- A new study has shown that infusion of…

Argos reports immunogenicity results of AGS-004 in HIV program

DURHAM, N.C., July 26, 2017 -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform,…

Child living with HIV maintains remission without drugs since 2008

Child treated in infancy as part of NIH-funded study. A nine-year-old South African child who was diagnosed with HIV infection at one month of age and received anti-HIV treatment during…

1 2 3 9